Results 61 to 70 of about 238 (77)
Some of the next articles are maybe not open access.

Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.

Journal of Clinical Oncology, 2012
8513 Background: Ipilimumab (ipi), an antibody against cytotoxic T-lymphocyte-associated antigen-4, improves survival in patients (pts) with metastatic melanoma (MM); however, objective tumor responses are limited. NIBIT-M1 aims to investigate the efficacy and safety of ipi plus fotemustine (FTM), a cytotoxic alkylating drug, in pts with MM. Methods:
Di Giacomo AM   +16 more
openaire   +2 more sources

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT)

2010
Introduction: As for a consolidated tradition, the VII annual meeting of the NIBIT (acronym for the Network Italiano per la Bioterapia dei Tumori, Italian Network for Tumor Biotherapy) took place in the Certosa of Pontignano, a Tuscan Carthusian monastery near Siena, on 1–3 October 2009.
Maio M   +12 more
openaire   +1 more source

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study

Nature Genetics
Pleural mesothelioma (PM) has a poor prognosis and standard therapy with immune checkpoint inhibitors (ICIs) CTLA-4 and PD-1 is still clinically unsatisfying. No predictive biomarkers of ICI efficacy in PM are available yet. In the retrospective multicenter NIBIT-EPI-MESO study, multi-omics analysis of pre-ICI therapy tumor lesions from 91 patients ...
Luana Calabrò   +30 more
openaire   +5 more sources

Abstract LB-C009: Tumor Methylation Subtypes Predict the Clinical Outcome to Immunotherapy in Pleural Mesothelioma Patients From the NIBIT-EPI-MESO Study

Cancer Immunology Research
Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinical efficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous across PM subtypes.
Giovanna Sabella   +2 more
exaly   +2 more sources

Abstract CT236: Epigenetic Immune Reprogramming Overcomes PD-1 Resistance in Metastatic Melanoma Patients: The Phase II NIBIT-ML1 Study

Cancer Research
Abstract Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly reported that the hypomethylating agent (HMA) guadecitabine (G), a prodrug of decitabine (D), followed by ipilimumab (I), was safe and had promising clinical and tumor-immunomodulatory activity in ...
Danna Chan   +2 more
exaly   +2 more sources

Tumor methylation subtypes as a predictor of clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study.

Journal of Clinical Oncology
8052 Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinicalefficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous acrossPM subtypes. Tumor-intrinsic characteristics (
Luana Calabrò   +19 more
openaire   +1 more source

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Cancer Immunology, Immunotherapy, 2009
Maio M   +33 more
openaire   +5 more sources

Cancer Bio-Immunotherapy XVII Annual NIBIT (Italian Network for Tumor Biotherapy) Meeting, October 11–13 2019, Verona, Italy

Cancer Immunology, Immunotherapy, 2022
Pier Francesco Ferrucci   +2 more
exaly  

Cancer Immunity and Immunotherapy Beyond COVID-19

Cancer Immunology, Immunotherapy, 2023
Vincenzo Bronte, Silvia Dusi
exaly  

9305 ORAL A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma – the NIBIT-M1 Trial

European Journal of Cancer, 2011
A.M. Pi Giacomo   +9 more
openaire   +1 more source

Home - About - Disclaimer - Privacy